Updates

Sabin Vaccine Institute Names David Salisbury, Jeffrey P. Libson to Board of Trustees, Philip K. Russell Retires to Advisory Role

Submitted by Liz Powell on Thu, 2020-04-02 08:55

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that Professor David Salisbury and Jeffrey P. Libson have been named to the Board of Trustees and Retired Major General Philip K. Russell will transition from Trustee to Special Advisor after more than 25 years of service to the organization.

Read more about Sabin Vaccine Institute Names David Salisbury, Jeffrey P. Libson to Board of Trustees, Philip K. Russell Retires to Advisory Role

Responding to COVID-19 – A Statement by the Sabin Vaccine Institute

Submitted by Liz Powell on Fri, 2020-03-27 12:32

As those of us who work in immunization know, our actions as individuals may protect us from getting a disease, but it takes vigilance by the entire community to stop the disease from spreading. We have all had to face the reality of this responsibility lately.

Read more about Responding to COVID-19 – A Statement by the Sabin Vaccine Institute

Sabin Vaccine Institute Receives $10M Grant to Raise Confidence in Vaccines

Submitted by Greg Bodwell on Thu, 2020-03-12 09:45

WASHINGTON, D.C – The Sabin Vaccine Institute (Sabin) today announced it has received a three-year grant valued at $10.4 million to strengthen vaccine acceptance. In 2019, the World Health Organization identified vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – as one of the top 10 threats to global health.

Read more about Sabin Vaccine Institute Receives $10M Grant to Raise Confidence in Vaccines

Distributed Design, Centralized Learning: A WhatsApp Focus Group with EPI Managers

03.09.20

This post was written by Caroline Gezon, a Fellow at Gobee Group.

Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

Submitted by Liz Powell on Thu, 2020-03-05 09:37

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations.